Q1 2025 Madrigal Pharmaceuticals Inc Earnings Call Transcript
Key Points
- Madrigal Pharmaceuticals Inc (MDGL) reported strong first quarter 2025 net sales of $137 million, up 33% quarter over quarter.
- Rezdiffra, the first FDA-approved treatment for MASH, achieved over 80% commercial payer coverage and treated more than 17,000 patients in its first year.
- The company has successfully built a strong base of prescribers, with 70% of their top 6,000 targets having prescribed Rezdiffra.
- Madrigal Pharmaceuticals Inc (MDGL) is expanding its leadership in MASH with compelling two-year F4c data and ongoing pivotal outcomes trials.
- The company is well-positioned financially, ending the first quarter with $848.1 million in cash and marketable securities, supporting ongoing and future launches.
- SG&A expenses increased significantly to $167.9 million in Q1 2025, up from $80.8 million in Q1 2024, primarily due to commercial launch activities.
- The company anticipates gross-to-net discounts to increase throughout 2025 as they begin contracting with payers.
- There is uncertainty regarding the impact of potential competition from semaglutide (SEMA) once it gains label expansion for NASH.
- The European launch of Rezdiffra faces challenges, including responding to regulatory questions and potential differences in non-invasive testing acceptance compared to the FDA.
- Madrigal Pharmaceuticals Inc (MDGL) is actively seeking business development opportunities, which may impact cash flow and require careful financial management.
Good day and thank you for standing by. Welcome to Madrigal Pharmaceuticals first quarter 2025 earnings conference call. (Operator Instructions) As a reminder, today's conference call is being recorded. I would now like to introduce Ms. Tina Ventura, Chief Investor Relations Officer. Please go ahead.
Thank you, Tawana. Good morning, everyone, and thank you for joining us to discuss Madrigal's first quarter 2025 earnings. We issued a press release this morning and I have a slide deck that accompanies this webcast, which we'll post on the investor relations section of our website right after the call.
On the call with me today is Bill Sibold, Chief Executive Officer; and Mardi Dier, Chief Financial Officer. They'll provide prepared remarks, and then we'll take your questions. We plan to keep today's call to about 45 minutes.
Please note on slide 2, we will be making certain forward-looking statements today. We refer you to our SEC filings for a discussion of the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
